Neurogene (NGNE) Cash & Equivalents (2013 - 2026)

Neurogene has reported Cash & Equivalents for 14 years, with the latest figure at $124.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 75.44% year-over-year to $124.2 million; the trailing twelve-month figure through Mar 2026 stood at $124.2 million (up 75.44% YoY), and the FY2025 full-year result was $103.8 million, down 23.97% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $124.2 million, up from $103.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $150.1 million in Q1 2024, with the low at $25.2 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $85.9 million across 5 years, with a median of $77.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 73.96% — and 2024, when it surged 323.0%.
• Neurogene's Cash & Equivalents stood at $82.0 million in 2022, then jumped by 80.7% to $148.2 million in 2023, then declined by 7.84% to $136.6 million in 2024, then retreated by 23.97% to $103.8 million in 2025, then advanced by 19.56% to $124.2 million in 2026.
• The last three Cash & Equivalents figures came in at $124.2 million (Q1 2026), $103.8 million (Q4 2025), and $71.0 million (Q3 2025), per Business Quant data.